|
|
 Previous Article | Table of Contents | Next Article 
Suppression of Cell Proliferation and the Expression of a
bcr-abl Fusion Gene and Apoptotic Cell Death in a New Human
Chronic Myelogenous Leukemia Cell Line, KT-1, by Interferon-
Kohsuke Yanagisawa,
Hayato Yamauchi,
Masahiko Kaneko,
Hidehisa Kohno,
Hitoshi Hasegawa, and
Shigeru Fujita
From the First Department of Internal Medicine, School of Medicine,
Ehime University, Ehime; and the Department of Internal Medicine,
Uwajima City Hospital, Ehime, Japan
A new human leukemia cell line, KT-1, was established from a patient
in the blastic crisis phase of chronic myelogenous leukemia (CML). This
cell line had a positive reaction for intracytoplasmic myeloperoxidase
and two Philadelphia chromosomes (Ph) [t(9;22)(q34;q11)] and lacked normal copies of chromosomes 9 and 22. Molecular
characterization of the breakpoint in the t(9;22)(q34;q11) showed that
KT-1 had a bcr-2/abl-2 splice junction. When the KT-1 cells
were cultured with interferon (IFN)- or IFN- , the growth of the
cells were dose-dependently suppressed. IFN- and IFN- exerted
synergistic suppressive effects on the growth of KT-1 cells.
Furthermore, IFN- suppressed the expression of the bcr-abl
fusion gene in KT-1 cells, and induced G1 cell-cycle arrest and
apoptotic cell death. The KT-1 cell line should be a valuable tool for
studying the molecular mechanism of the suppression of Ph
clone cells from CML by IFN.
Blood, Vol. 91 No. 2 (January 15), 1998:
pp. 641-648
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Yan, J.-K. Luo, K. J. Ritchie, I. Sakai, K. Takeuchi, R. Ren, and D.-E. Zhang
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling
Blood,
July 1, 2007;
110(1):
305 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sakai, K. Takeuchi, H. Yamauchi, H. Narumi, and S. Fujita
Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells
Blood,
September 26, 2002;
100(8):
2926 - 2931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Pane, I. Mostarda, C. Selleri, R. Salzano, A. M. Raiola, L. Luciano, G. Saglio, B. Rotoli, and F. Salvatore
BCR/ABL mRNA and the P210BCR/ABL Protein Are Downmodulated by Interferon-alpha in Chronic Myeloid Leukemia Patients
Blood,
October 1, 1999;
94(7):
2200 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Mayer, A. Verma, I. M. Grumbach, S. Uddin, F. Lekmine, F. Ravandi, B. Majchrzak, S. Fujita, E. N. Fish, and L. C. Platanias
The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-alpha in BCR-ABL-expressing Cells
J. Biol. Chem.,
July 20, 2001;
276(30):
28570 - 28577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
